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Abstract Concurrent use of bisphosphonate therapy
reduces the anabolic effect of teriparatide. Consequently, in
clinical practice bisphosphonates are discontinued and
teriparatide therapy held for a few months to allow bone
turnover to increase. We aimed to evaluate the effect of
prior bisphosphonate exposure and the effect of bis-
phosphonate wash-out on the treatment response to teri-
paratide. Thirty-nine patients with primary osteoporosis
(mean age 63.6 ± 14.0 years), including 26 patients pre-
viously treated with oral bisphosphonates (median duration
53 months) and 13 bisphosphonate-naı¨ve patients were
started on teriparatide (20 lg daily) and followed pro-
spectively over 12 months. The primary study outcome
was change in bone formation markers (PINP, bone ALP,
osteocalcin). Secondary outcomes included changes in
bone resorption (bCTX) and 12-month changes in BMD.
Markers of bone formation increased early during teri-
paratide therapy and were followed by an increase in
bCTX (p \ 0.001). The magnitude of the increase in bone
markers was comparable in both patient groups irrespective
of prior bisphosphonate exposure; similarly, increases in
BMD after 12 months were not significantly different
between bisphosphonate-pretreated and bisphosphonate-
naı¨ve patients (lumbar spine 7.1 vs. 8.9%, p = 0.58; total
hip 4.1 vs. 1.1%, p = 0.48). The response of teriparatide
was not related to the duration of bisphosphonate wash-out
(median duration 4.2 months). This study confirms that
beneficial effects of teriparatide on intermediate bone
endpoints can be translated into clinical practice with less
constringent methodological circumstances than in RCTs.
Furthermore, as bisphosphonate wash-out does not appear
to influence the treatment effect, teriparatide therapy can be
started immediately after ceasing bisphosphonate therapy
and wash-out.
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Introduction
Teriparatide (human recombinant PTH 1–34) stimulates
predominantly bone-forming osteoblasts. When given
intermittently, teriparatide induces bone formation by
increasing the rate of bone remodeling, trabecular con-
nectivity and cortical bone thickness, ultimately resulting
in improved bone strength [1–3]. Randomized trials con-
firmed the beneficial effect of teriparatide with reduced
incidence of osteoporotic fracture in both postmenopausal
women [4] and in men [5]. The anabolic effect of teri-
paratide is, at least in part, mirrored by changes in bio-
chemical markers of bone turnover. Teriparatide treatment
is associated with an early increase in biochemical markers
of bone formation and a delayed increase in markers of
bone resorption [6–8]. This ‘‘anabolic window’’ apparently
is thought to be responsible for the PTH-induced increase
in bone mass and the preservation of bone architecture.
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In many countries in Europe, including Switzerland, ter-
iparatide use is restricted to patients with severe osteoporosis
suffering incident fractures despite antiresorptive therapy.
Hence, many candidates for PTH therapy are on long-term
bisphosphonate therapy. Prolonged suppression of bone
remodeling due to bisphosphonates may blunt the initial
anabolic effects of teriparatide. This is supported by previous
studies demonstrating a diminished response to recombinant
PTH with respect to BMD and bone turnover in patients with
concurrent [7, 9], alternate [10] or prior [11] bisphosphonate
exposure. These observations led to the clinical practice
opinion that bisphosphonates should be discontinued and
teriparatide treatment ‘‘held’’ for a 6- to 12-month period to
allow turnover to increase [12, 13]. However, data investi-
gating whether prior bisphosphonate wash-out is associated
with differing treatment outcome are limited [14].
Clinical trials, i.e., randomized and placebo-controlled,
are recognized as the standard means of establishing effi-
cacy of treatment agents. Due to several circumstances,
however, these data may not be valid to patients presenting
in clinical practice. In order to eliminate factors that might
confound treatment effects, clinical trials commonly
employ inclusion and exclusion criteria. In clinical prac-
tice, however, only a minority of patients with osteoporosis
(about 20%) would be accepted for inclusion in these trials
[15]. In general, teriparatide patients are older, in poorer
health and are likely to have more severe osteoporosis than
bisphosphonate patients [16]. In randomized trials bone
markers were only assessed at the end of the study period
in one run, thereby decreasing intra- and interassay vari-
ability. In order to monitor anti-osteoporotic treatment in
clinical practice, however, one relies on continuous anal-
yses of clinical endpoints, including bone turnover mark-
ers. This raises the question whether the observed changes
of clinical endpoints in randomized trials, such as changes
in bone turnover markers, may be extrapolated to changes
observed in daily routine with less constringent real-life
circumstances.
The aim of this study was first to determine the effect of
teriparatide in osteoporotic patients previously treated with
oral bisphosphonates as compared to treatment-naı¨ve
patients and secondly to assess whether duration of bis-
phosphonate wash-out prior to commencement of teri-
paratide therapy is related to treatment outcome as assessed
by changes in bone markers and bone density.
Methods
Study design and participants
This study was a prospective, open label, nonrandomized,
12-month trial examining the effects of rhPTH (1–34) in
patients with primary osteoporosis including both patients
previously treated with oral bisphosphonates (alendronate
70 mg weekly or risedronate 35 mg weekly; n = 26) and
treatment-naı¨ve patients (n = 13). The study was con-
ducted in a single Endocrine and Osteoporosis Outpatient
Clinic, Basel, Switzerland. Patients at our center who were
considered for teriparatide therapy were consecutively
enrolled into the study. In Switzerland, the Federal Office
of Public Health restricts the reimbursement of teriparatide
to those patients who fail to respond to prolonged treatment
with bisphosphonates. Nevertheless, the decision for teri-
paratide treatment was based on the severity of disease
after individualized clinical assessment.
Participants were women (n = 20) and men (n = 19)
with a prior lumbar spine or total hip BMD T-score of
B-2.5 SD and/or at least one fragility fracture. Patients
were excluded if osteoporosis workup revealed a secondary
cause for their osteoporosis (including glucocorticoid
induced osteoporosis), or if they had a history of metabolic
bone disease or vitamin D deficiency.
All patients received daily self-administered subcuta-
neous injections of teriparatide 20 lg in addition to daily
calcium (500 mg) and vitamin D (400 IU) for 1 year. Two
postmenopausal women (both in the bisphosphonate-naı¨ve
group) remained on long-term estrogen replacement ther-
apy. The local Ethics Committee for Human Studies
approved the protocol, and informed consent was obtained
from all participants.
Baseline and follow-up measures
At baseline we obtained information on demographics,
health history and medication use. On the study day,
morning blood samples were drawn after an overnight fast,
including routine chemistry and biochemical markers of
bone turnover [N-terminal propeptide of type I procollagen
(PINP), bone-specific alkaline phosphatise (BAP), osteo-
calcin (OC) and C-terminal type I collagen telopeptide
telopeptide (CTX)].
Bone mineral density at the lumbar spine and hip were
evaluated by dual X-ray absorptiometry (DXA) using a
Lunar Expert densitometer (Lunar, Madison, WI). A single
densitometer was used throughout the study. To assess the
short-term precision of the system in this population, a
single repeat measurement in 20 patients was performed
[17]. The coefficient of variation of individual measure-
ments was 1.1% for the spine, 1.4% for the femoral neck,
1.9% for the trochanteric region and 1.1% for the total hip.
Follow-up visits were scheduled at 1, 4–6 and
12 months after the start of teriparatide therapy. Serum
biochemical tests were obtained at all visits, whereas BMD
was measured before and at the end of the study after
12 months.
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Laboratory measurements
Calcium and creatinine were analyzed by standard method
on an autoanalyzer (Hitachi System 704 analyzer; Roche
Diagnostics, Basel, Switzerland). Serum bone-specific
alkaline phosphatase (BAP) was determined by an ELISA
(ALKPHASE-B ELISA, Quidel, San Diego, CA). The
intra- and interassay variations were \5.8 and 7.6%,
respectively [18]. The parameters beta-CrossLaps (CTX),
N-MID-Osteocalcin (OC), N-terminal propeptide of type I
collagen (PINP) and intact parathyroid hormone (iPTH)
were measured in serum with electrochemiluminescence
immunoassays (ECLIA) on the automated analyzer Elecsys
2010 (Roche Diagnostics, Rotkreuz, Switzerland) [19, 20].
The intra- and interassay variation was 2.4–7.2% for CTX,
1.1–5.9% for OC, 1.7–4.0% for PINP and 1.7–5.5% for
intact PTH, respectively. All laboratory analyses were
carried out as duplicates.
Statistical analysis
The primary study outcome was the change from baseline
in bone formation markers (PINP, BAP, OC) after 1, 4–6
and 12 months. Secondary outcomes included changes in
serum CTX levels (after 1, 4–6 and 12 months), 12-month
changes from baseline in lumbar spine and hip BMD, and
comparisons of all these outcome variables between the
two study groups.
Data are shown as mean ± SD for normally distributed
variables and as median and interquartile ranges for not
normally distributed variables, respectively. Unpaired t test
(two-sided), or Mann–Whitney U test in the case of non-
parametric distributions, was used to identify differences
among patient groups. Changes in bone marker levels
during teriparatide therapy were estimated in a repeated
measures ANOVA model. Correlations between change in
bone marker levels and change in BMD or duration of
bisphosphonate wash-out were examined by Spearman
rank correlation coefficients. p \ 0.05 was considered
statistically significant. Analyses were done using SPSS
software Version 15.0 (SPSS Inc. Chicago, IL).
Results
Baseline characteristics
Thirty-nine consecutive patients with primary osteoporosis
(20 women, 19 men; mean age 63.6 ± 14.0 years) have
been started on teriparatide therapy and were followed for
12 months. Thirteen patients were bisphosphonate naı¨ve,
whereas 26 subjects had prior bisphosphonate use
[alendronate n = 24; risedronate n = 2; median duration
of bisphosphonate therapy 53 months (range 3–
114 months)]. Bisphosphonate discontinuation was not
standardized; the median bisphosphonate wash-out time
was 4.2 months (range 0–10 months), which did not cor-
relate with the duration of bisphosphonate treatment
(r = 0.17, p = ns).
Patient characteristics at baseline, including serum lev-
els of bone turnover markers and BMD at the lumbar spine
and femoral neck, are presented in Table 1. Patients pre-
treated with bisphosphonates and bisphosphonate-naı¨ve
patients were similar for age, BMI, dietary calcium intake
and BMD measures. As expected, the prior bisphosphonate
group had significantly lower serum levels for biochemical
markers of bone formation (PINP p = 0.01; OC
p = 0.007) and bone resorption (CTX p = 0.03). Severity
of osteoporosis as assessed by number of patients with
prevalent vertebral fractures (81 vs. 85%) and mean
number of vertebral fractures per patient (2.7 ± 1.8 vs.
2.2 ± 1.7) was comparable between pretreated and bis-
phosphonate-naı¨ve patients (p = 0.95).
Bone turnover response to teriparatide
In response to teriparatide, overall biochemical markers of
bone formation increased early in the course of therapy
with peak levels after 4–6 months (PINP, BAP, OC;
univariate ANOVA, p \ 0.001) and were followed by
an increase in bCTX (p \ 0.001) (Fig. 1). In the prior
bisphosphonate group, serum levels of PINP and OC
increased significantly from baseline with elevated levels
at all time points during follow-up, whereas serum con-
centrations of CTX and BAP increased significantly only
after 4–6 or 12 months, respectively. In bisphosphonate-
naı¨ve patients median changes in bone markers were
numerically similar. The magnitude of the increase in all
serum markers was comparable between both treatment
groups irrespective of prior bisphosphonate treatment
(p [ 0.05 at all time points, Fig. 1). Specifically, absolute
and relative increases of markers of bone turnover were
comparable between bisphosphonate-pretreated and bis-
phosphonate-naı¨ve patients, although baseline serum
concentrations were significantly lower in patients with
bisphosphonate pretreatment.
BMD response to teriparatide
Twelve months after teriparatide therapy, lumbar spine
BMD increased significantly in both patients with prior
bisphosphonate treatment (p = 0.001) and treatment-naı¨ve
patients (p = 0.015). Bone mineral density at the femoral
neck and total hip increased in all treatment groups; how-
ever, significant changes were observed only at the femoral
neck in bisphosphonate pre-treated patients (p = 0.02).
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Mean percent changes in lumbar spine BMD were not
significantly different between the bisphosphonate-treated
patients and the bisphosphonate-naı¨ve patients (7.1 vs.
8.9%, p = 0.58, Fig. 2). Similarly, increases in BMD at the
total hip (4.1 vs. 1.1%, p = 0.48) and femoral neck (6.5 vs.
1.6%, p = 0.24) were comparable in both treatment
groups. Increases in BMD did not correlate with the
observed changes in bone marker levels during teriparatide
therapy in either group, nor were they associated with bone
marker levels at baseline.
Correlations between duration of bisphosphonate
wash-out and teriparatide response
To evaluate a potential influence of the duration of bis-
phosphonate wash-out prior to the initiation of teriparatide
Table 1 Baseline
characteristics in patients
starting teriparatide therapy
with or without prior
bisphosphonate (alendronate,
risedronate) therapy
p values are given for
differences between patients
with and without
bisphosphonate treatment prior
to teriparatide therapy. Values
are expressed as mean ± SD or
median (IQR), as appropriate
Prior bisphosphonate
treatment
No pretreatment p value
N 26 13
Age (years) 65.3 ± 14.2 60.5 ± 13.6 0.33
BMI (kg/m2) 23.8 ± 6.4 24.1 ± 3.1 0.86
Dietary calcium (mg/day) 959 ± 347 977 ± 335 0.88
Time since menopause (years, n = 20) 18.8 ± 13.3 8.6 ± 16.6 0.19
Duration bisphosphonate treatment (mts) 53.0 (25.8, 70.8) –
Duration bisphosphonate wash-out (mts) 4.2 (1.3, 6.8) –
Calcium (mmol/l) 2.45 (2.40, 2.55) 2.52 (2.35, 2.57) 0.61
PTH intact (pg/ml) 33.3 (27.6, 43.5) 31.7 (23.4, 42.0) 0.83
S-PINP (lg/ml) 24.4 (18.2, 35.1) 42.0 (23.7, 67.7) 0.01
S-Bone ALP (lg/l) 20.4 (11.7, 30.7) 17.6 (14.2, 31.6) 0.53
S-OC (ng/ml) 16.1 (12.7, 20.0) 25.0 (19.0, 31.7) 0.007
S-bCTX (ng/ml) 0.19 (0.14, 0.29) 0.35 (0.13, 0.45) 0.03
BMD spine (g/cm2) 0.797 ± 0.118 0.793 ± 0.108 0.92
BMD femoral neck (g/cm2) 0.720 ± 0.117 0.789 ± 0.106 0.08
Vertebral fractures (number of patients, %) 21 (81%) 11 (85%) 1.00
Vertebral fractures (mean number of fx per
patient)
2.7 ± 1.8 2.2 ± 1.7 0.95
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therapy, pretreated patients (n = 26) were divided in ter-
tiles according to their duration of the bisphosphonate
wash-out time (less than 2, 2–6 months and more than
6 months). Irrespective of the duration, bisphosphonate
wash-out increases in serum marker of bone formation and
bone resorption after 4–6 months (Fig. 3) and increases in
BMD at the spine and the femoral neck after 12 months
(Fig. 4) were similar in all tertile groups (p = ns for trend
among tertiles). Correlation data showed no significant
association between the duration of bisphosphonate wash-
out and the increase in bone turnover markers either after 1,
4–6 or 12 months (except for an inverse correlation
between bisphosphonate wash-out time and the change in
CTX after 12 months; r = -0.45, p = 0.03).
Safety
Three patients (7.7%) reported side effects considered to be
related to teriparatide therapy, including nausea (n = 3),
myalgia (n = 2) and arthralgia (n = 1). Hypercalcemia
during teriparatide therapy was observed in five patients
(12.8%): one (2.6%) treatment-naı¨ve and four (10.2%) with
prior alendronate therapy. In all patients, hypercalcemia
was considered mild and peaked off while continuing
teriparatide.
Discussion
In this prospective, open-label study in postmenopausal
women and in men with osteoporosis, teriparatide treat-
ment for 12 months was associated with significant
increases in bone formation markers and lumbar spine
BMD irrespective of prior bisphosphonate use. Impor-
tantly, changes in bone markers and BMD were similar in
patients with previous long-term bisphosphonate therapy
(median duration 53 months) as compared to treatment-
naı¨ve patients. Furthermore, in patients with prior bis-
phosphonates, the response to teriparatide was not related
to the duration of bisphosphonate wash-out time. Our
findings indicate that prior antiresorptive treatment does
not substantially alter the response to teriparatide and that
patients with increased fracture risk may be immediately
changed to anabolic treatment after bisphosphonates have
been ceased.
Teriparatide induced changes on lumbar spine BMD to a
comparable extent as has been shown for treatment-naı¨ve
patients in randomized trials [4, 7]. After 12 months, areal
lumbar spine BMD increased by 7.1% in patients previ-
ously treated with oral bisphosphonates and by 8.3%
in treatment-naı¨ve patients. Importantly, the increase in
lumbar spine BMD was not different between the treatment
groups (p = 0.58), an observation that has also been made
by Middleton et al. [21] in 52 postmenopausal women
followed in clinical practice. Nevertheless, our results are
in contrast to recent findings from another open-label
clinical trial indicating that patients previously treated with
bisphosphonates may have blunted BMD response to teri-
paratide [22]. The mean gain in spine BMD over 12 and
24 months in the EUROFORS Study was significantly
greater in the treatment-naı¨ve group (11.1 and 13.1%,
respectively) than in the group of patients pretreated with
antiresorptives (8.6 and 10.2%, respectively). Despite
similar baseline characteristics differences in BMD
response may be attributed to differences in study design.
Obermayer-Pietsch et al. enrolled postmenopausal women
only and allowed patients to be treated with various anti-
resorptive agents, including intravenous bisphosphonates.
Furthermore, the median duration of oral bisphosphonate
pretreatment was 5–26 months for alendronate and 5–
20 months for risedronate as compared to 53 months in our
study, which may account further for differences in study
outcomes. Nevertheless, due to the smaller size, our study
may be underpowered to detect a difference in BMD
response between bisphosphonate-pretreated and treat-
ment-naı¨ve patients.
Previous studies have reported that teriparatide-induced
changes at skeletal sites with a high proportion of cortical
bone are less than at sites with predominantly trabecular
bone [9, 11, 23, 24]. It is assumed that at cortical sites
teriparatide induces the simultaneous periostal apposition
of new bone matrix and endosteal resorption of old bone
matrix. Hence, patients on antiresorptives may experience
more pronounced early decreases in hip BMD after starting
teriparatide [14]. In part, this might explain the modest
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increase in femoral neck and hip BMD in our study,
although we did not observe a transient decrease in hip
BMD during the first 12 months of teriparatide, as has been
shown by others [14, 22, 25].
Early changes in bone turnover markers with PTH
therapy in treatment-naı¨ve patients have been shown to be
associated with greater increases in areal [26, 27] and
volumetric [28] BMD. In this respect we were interested to
know whether prior bisphosphonate therapy may influence
the teriparatide response on bone markers. In fact, con-
current or prior alendronate therapy has been shown to
attenuate the short-term increase in bone formation mark-
ers [7, 11]. In our study we observed a significant anabolic
effect of teriparatide on bone turnover markers regardless
of previous long-term exposure to bisphosphonate treat-
ment. Specifically, bone formation markers increased
comparably during teriparatide therapy in both pretreated
and treatment-naı¨ve patients, although patients with pre-
vious bisphosphonate therapy had significantly lower bone
marker levels at baseline. An early and robust increase in
bone formation markers was seen already within the first
6 months of treatment. As expected, changes in formation
markers were followed by an increase in serum CTX levels
in accordance with findings from randomized trials
[24, 29–31]. Similarly, Middleton et al. observed no dif-
ference in the teriparatide response on serum PINP levels
after 3 and 6 months, although a trend towards a smaller
increase in patients with prior bisphosphonate therapy as
compared to treatment-naı¨ve patients has been observed.
Overall, bisphosphonate exposure did not prevent a
significant increase in bone formation markers (including
serum PINP) during the first months of teriparatide therapy.
Irrespective of prior antiresorptive treatment, short-term
increases in bone formation markers after 1–6 months did
not correlate with the observed changes in BMD after
12 months of teriparatide therapy. Whereas our findings
are in contrast to previously mentioned studies in treat-
ment-naı¨ve patients, they are consistent with reports
showing a lack in the association between increase in bone
formation markers and BMD in previous alendronate or
risedronate users [11, 25]. Although we did not observe an
influence of prior bisphosphonate treatment on the anabolic
response to lumbar spine BMD we cannot exclude that the
full relevance of early bone marker changes to the change
in BMD may be only apparent after prolonged teriparatide
treatment, i.e., 18–24 months. Importantly, no studies are
available investigating the efficacy of teriparatide in
reducing fracture risk in relation to early changes in sur-
rogate markers and the potential influence of previous
long-term antiresorptive therapy.
Due to the observation that teriparatide response may be
blunted in previous bisphosphonate users, some clinicians
advocate that teriparatide treatment should be withheld for
6 to 12 months after stopping bisphosphonates to allow
bone turnover to recover [12, 13]. Acknowledging that the
suppressive effect of bisphosphonates may last for several
months after treatment withdrawal [32] and the fact that the
risk of incident fractures in patients with severe osteopo-
rosis may increase questions the need for a bisphosphonate
wash-out period. In fact, we found no correlation between
400
500
400
500
∆PINP ∆Bone ALP
100
200
300
100
200
300p=ns
p=ns
400
500
400
500
0 0
∆OC ∆βCTX
200
300
200
300
M
ed
ia
n 
ch
an
ge
 (%
)
p=ns
p=ns
0
100
0
100
<2 2-6 >6 <2 2-6 >6
Duration wash-out (mts) Duration wash-out (mts)
Fig. 3 Changes in bone marker
levels after 4–6 months of
teriparatide therapy according to
duration of bisphosphonate
wash-out in patients with
previous bisphosphonate
therapy. Duration of
bisphosphonate wash-out is
given in tertiles of the entire
cohort of patients with prior
bisphosphonate use (n = 26),
i.e., less than 2, 2–6 months and
more than 6 months.
Mean ± SEM
J Bone Miner Metab (2010) 28:68–76 73
123
the duration of bisphosphonate wash-out and the early
increase in bone turnover markers as well as the increase in
lumbar spine and hip BMD after 12 months. The median
time interval between the last bisphosphonate dose and
commencement of teriparatide was 4.2 months. Neverthe-
less, even longer discontinuation for more than 6 months
(up to 10 months) did not alter teriparatide response.
As compared to previous studies, this is the first study
within a clinical setting investigating longer lag times
between stopping bisphosphonates and starting teripara-
tide. In studies by Middleton et al. [21] and Boonen et al.
[14] most patients initiated teriparatide therapy within
1 month after discontinuing antiresorptive treatment. In the
latter study, the duration of bisphosphonate wash-out was
not associated with BMD increase [14]; however, each
additional week of lag time before starting teriparatide was
associated with a 0.9% increase in PINP levels and 0.4%
increase in BAP levels. In view of our negative findings
with longer bisphosphonate washout periods, the rather
small changes in marker levels within the first weeks
before starting teriparatide in the study by Boonen et al.
and the lack of any association with BMD changes may
question the clinical significance of this observation. With
these findings we suggest that teriparatide treatment may
be started immediately after bisphosphonates have been
stopped without the need for prior bisphosphonate
washout.
The present study’s findings should be interpreted within
the context of its strengths and limitations. Importantly this
study assessed teriparatide response in consecutive patients
who had substantial prior oral bisphosphonate treatment for
a longer duration as compared to patients in the EUROF-
ORS Study (median duration 53 vs. 20–26 months) [22].
Our study is limited by its non-randomized, open-label
design; however, this resembles more accurately the real-
life circumstances one would see in clinical practice,
enhancing its clinical validity. Secondly, the use of bis-
phosphonate therapy before commencing teriparatide was
not randomized, and patients with both alendronate and
risedronate have been included. Due to the low number of
patients overall, and specifically, the low numbers of
patients on prior risedronate treatment (n = 2), subgroup
analyses to evaluate differences in anabolic responsiveness
to teriparatide in relation to the type and antiresorptive
potency of prior bisphosphonate exposure are not feasible.
Furthermore, due to unbalanced gender distribution within
the patient groups, we were not in a position to test whether
gender differences might have affected the study findings.
Thirdly, we did not assess adherence of prior bisphospho-
nate therapy and are therefore unable to exclude irregular-
ities in drug intake affecting subsequent teriparatide
response. At baseline, however, patients with prior bis-
phosphonate therapy had significantly lower bone turnover
marker levels as compared to treatment-naı¨ve patients,
indicating accurate compliance to prior treatment regimens.
Finally, our study is not powered to assess the effect of prior
bisphosphonate use or the effect of bisphosphonate wash-
out on fracture rates or to identify subtle differences in
BMD or markers of bone remodeling.
In conclusion, treatment with teriparatide for 12 months
is associated with significant changes in bone formation
markers and in lumbar spine BMD regardless of prior long-
term bisphosphonate treatment. No blunting of teriparatide
response was observed within the first year of therapy.
Importantly the change in bone marker levels (within
6 months) and the change in BMD (after 12 months) was
independent from the lag time between discontinuation
of bisphosphonates and the initiation of teriparatide
therapy. With these findings we suggest that teriparatide
treatment may be started immediately after stopping
bisphosphonates.
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